Published by Frank Prenesti on 5th January 2022
(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.
URL: http://www.digitallook.com/dl/news/story/32371113/...